^
    Back
    Association details:
    Biomarker:SMAD4 mutation
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 6161: PARP inhibition enhances radiotherapy of SMAD4 deficient human head and neck squamous cell carcinomas in experimental models

    Published date:
    05/15/2020
    Excerpt:
    HNSCC cell lines with SMAD4 homozygous deletion were sensitive to olaparib. In vivo, olaparib or RT monotherapy reduced tumor volumes in SMAD4 mutant but not SMAD4 positive tumors.
    DOI:
    10.1158/1538-7445.AM2020-6161